Inyx EV/EBIT

Mitä Inyx tekee? Inyx, Inc. generates revenue through the development and acquisition of niche pharmaceutical products and drug delivery systems, primarily targeting respiratory and dermatological therapeutic areas. The company offers a range of products including Metered Dose Inhalers (MDIs) using CFC and HFA propellants, Dry Powder Inhalers (DPIs), Metered Dose Pump Sprays for nasal and oral use, Hydrocarbon Foam Aerosols, Saline Aerosols, Sterile Solutions/Injectables, and Solid Dose formulations. Additionally, Inyx provides specialty consulting services such as Formulation Services, Analytical Development Validation, Stability Services, Regulatory Support, and Integrated Project Management to pharmaceutical clients seeking expertise in product development and regulatory compliance. The primary buyers of Inyx's products and services are pharmaceutical companies requiring niche drug delivery solutions and specialized development services. These clients include both established pharmaceutical firms and emerging biotech companies focused on respiratory and dermatological treatments. Inyx's portfolio of drug delivery systems and formulation services caters to the specific needs of these clients, enabling them to bring innovative products to market more efficiently. Inyx's business model leverages its expertise in niche drug delivery systems to develop both prescription and over-the-counter pharmaceutical products. The company's offerings span multiple therapeutic areas, with a strong emphasis on respiratory and dermatological applications. By combining its proprietary delivery technologies with comprehensive development services, Inyx supports clients throughout the product lifecycle, from initial formulation to regulatory approval and market launch. Inyx on yksi Eurpooliin suosituimmista yhtiöistä.